Biopharma Business

Tag "Heart Failure Treatment"

Global European Rights to AstraZeneca’s Heart Failure Treatment Acquired by Recordati for $300M

    Global European Rights to AstraZeneca’s Heart Failure Treatment Acquired by Recordati for $300M

Recordati announced that it has entered into an agreement with AstraZeneca for the acquisition of the rights to Seloken®/Seloken® ZOK (metoprolol succinate) and associated Logimax® fixed dose combination (metoprolol succinate

Read Full Article

Upcoming Events

[eventlist]

The Magazine

New Subscriber

Subscribe Here



Advertisements